医学
不利影响
耐火材料(行星科学)
内科学
临床研究阶段
毒性
实体瘤疗效评价标准
加药
淋巴瘤
肺癌
外科
胃肠病学
物理
天体生物学
作者
Jianliang Yang,Lihou Dong,Sheng Yang,Xiaohong Han,Ying Han,Shiyu Jiang,Jiarui Yao,Zhishang Zhang,Shuxiang Zhang,Peng Liu,Yan Qin,Hai Wu,Hui Feng,Sheng Yao,Yan Ping Sun,Haifeng Song,Yuankai Shi
标识
DOI:10.1016/j.ejca.2020.01.028
摘要
Purpose This is a first-in-human phase I study investigating the safety and efficacy of toripalimab, a humanized monoclonal antibody against the programmed cell death-1 (PD-1) receptor, in Chinese patients with advanced or recurrent malignant tumor refractory to standard treatment. Patients and methods During dose escalation, patients received a single-dose intravenous infusion of toripalimab for 56 days followed by multidose infusions every two weeks. The planned dosing groups were 1, 3 and 10 mg/kg. During dose expansion, patients received toripalimab every two weeks. Clinical response was evaluated by investigators every 6 weeks. Results Thirty-three patients were enrolled, including 12 patients with alveolar soft part sarcoma (ASPS), seven with non–small-cell lung cancer and 11 with lymphoma. Patients were heavily pretreated with a median of 3 prior lines of systemic treatments. Toripalimab was well tolerated without dose-limiting toxicity. All patients experienced treatment-related adverse events. Grade 3 and above treatment-related adverse events occurred in six (18.2%) patients. Among 22 solid tumors, the objective response rate (ORR) was 22.7% per RECIST v1.1. The ORR was 90.9% in 11 lymphoma patients per IWG 2007. The median duration of response was 21.5 months. The median progression-free survival was 5.7 months for solid tumors and 8.3 months for lymphomas. The median OS was not reached for all patients and the lymphoma subgroups. The median OS was 34.7 months for patients with ASPS. Conclusion Toripalimab was well tolerated up to 10 mg/kg Q2W without dose-limiting toxicity and showed promising and durable antitumour activities in patients with ASPS and lymphoma, who were heavily pretreated. Clinical trial information ClinicalTrials.gov Identifier: NCT02836834.
科研通智能强力驱动
Strongly Powered by AbleSci AI